| First Author | Pacienza N | Year | 2012 |
| Journal | Mol Ther | Volume | 20 |
| Issue | 7 | Pages | 1454-61 |
| PubMed ID | 22472949 | Mgi Jnum | J:347763 |
| Mgi Id | MGI:7627496 | Doi | 10.1038/mt.2012.64 |
| Citation | Pacienza N, et al. (2012) Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther 20(7):1454-61 |
| abstractText | Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal A) activity that results in progressive globotriaosylceramide (Gb(3)) deposition. We created a fully congenic nonobese diabetic (NOD)/severe combined immunodeficiency (SCID)/Fabry murine line to facilitate the in vivo assessment of human cell-directed therapies for Fabry disease. This pure line was generated after 11 generations of backcrosses and was found, as expected, to have a reduced immune compartment and background alpha-gal A activity. Next, we transplanted normal human CD34(+) cells transduced with a control (lentiviral vector-enhanced green fluorescent protein (LV-eGFP)) or a therapeutic bicistronic LV (LV-alpha-gal A/internal ribosome entry site (IRES)/hCD25). While both experimental groups showed similar engraftment levels, only the therapeutic group displayed a significant increase in plasma alpha-gal A activity. Gb(3) quantification at 12 weeks revealed metabolic correction in the spleen, lung, and liver for both groups. Importantly, only in the therapeutically-transduced cohort was a significant Gb(3) reduction found in the heart and kidney, key target organs for the amelioration of Fabry disease in humans. |
